COLUMBIA, Md., Feb. 17, 2011 /PRNewswire/ -- Martek Biosciences
Corporation (Nasdaq: MATK), a leader in the innovation,
development, production and sales of high-value products from
microbial sources that promote health and wellness through
nutrition, announced today that it has been inducted into the
inaugural Small Business Innovation Research (SBIR) Hall of Fame, a
program under the U.S. Small Business Administration. Martek
Biosciences was recognized for its success in research, innovation
and commercialization within the SBIR program. Martek was honored
at the national inductee ceremony held on February 15, 2011 in Washington, DC, followed by a White House
reception.
"We are honored to be one of only eight companies inducted into
the first-ever SBIR Hall of Fame," said Steve Dubin, CEO of Martek Biosciences. "Our
success over the past 26 years has been realized in part from the
funding and support we received through the SBIR program during our
early start-up stage. What started with a few visionary and
passionate scientists is now a company with more than 600
employees, revenues of more than $450
million and a thriving and robust technology pipeline."
SBIR is a highly-competitive program that encourages small
businesses to explore their technological potential and provides
the incentive to profit from its commercialization. By including
qualified small businesses in the nation's R&D arena, high-tech
innovation is stimulated and the United
States gains entrepreneurial spirit and grows jobs as it
meets its specific research and development needs.
All SBIR Hall of Fame award winners were selected by the SBA
based on the recommendations of a panel of judges. Inductees were
evaluated based on a company's technical innovation, business
impact, broader social and economic benefit, degree of impact and
longevity.
About Martek
Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the
innovation, development, production and sales of high-value
products from microbial sources that promote health and wellness
through nutrition. The company is the world's leading
provider of algal DHA omega-3 with its flagship product,
life'sDHA™, a sustainable and vegetarian source of algal DHA
omega-3 important for brain, heart and eye health throughout life,
for use in foods, beverages, infant formula, and supplements. The
company also produces life'sARA™ (arachidonic acid), an
omega-6 fatty acid, for use in infant formula and growing up milks.
Additionally, Martek's subsidiary, Amerifit Brands, develops,
markets and distributes branded consumer health and wellness
products in major mass, club, drug, grocery and specialty stores
and holds leading brand positions in all of its key product
categories. For more information on Martek Biosciences, visit
http://www.martek.com/. For information about life'sDHA or
life'sARA products, visit www.lifesdha.com/ or
www.algaldha.com. For more information about Amerifit Brands, visit
www.amerifit.com.
Sections of this release contain forward-looking statements.
These statements are based upon numerous assumptions which Martek
cannot control and involve risks and uncertainties that could cause
actual results to differ. These statements should be understood in
light of the risk factors set forth in the company's filings with
the Securities and Exchange Commission, including, but not limited
to, the company's Form 10-K for the fiscal year ended October 31, 2010 and other filed reports on Form
10-K, Form 10-K/A, Form 10-Q and Form 8-K.
Contact:
|
Cassie France-Kelly
|
|
|
Public Relations
|
|
|
(443) 542-2116
|
|
|
media@martek.com
|
|
|
|
|
|
Kyle Stults
|
|
|
Investor Relations
|
|
|
(410) 740-0081
|
|
|
investors@martek.com
|
|
|
|
SOURCE Martek Biosciences Corporation